Monitoring of viral levels during therapy of hepatitis C

Authors

  • Gary L. Davis 3500 Gaston Ave.

    Corresponding author
    1. Division of Hepatology, Baylor University Medical Center, Dallas, TX
    • Dallas, TX 75246-2088. fax: 214-820-8168
    Search for more papers by this author
    • Dr. Davis has received clinical research support from Roche Laboratories, Schering Plough Research Institute, Human Genomic Sciences, Wyeth, and Bayer Laboratories.


Abstract

Alpha interferon therapy of chronic hepatitis C is typically accompanied by a biphasic decrease in hepatitis C virus (HCV) RNA levels: an initial rapid decline during the first 24 to 48 hours, and a second more gradual decline during the following weeks. The rate of second-phase decline correlates with ultimate response to interferon treatment. Thus, assessment of early virological response (EVR) may predict outcome. Data from 2 large clinical trials of peginterferon and ribavirin were combined and analyzed to determine the optimal definition of an EVR which, if not achieved, was associated with a low likelihood of a sustained virological response (SVR). A fall in HCV RNA level to undetectable or by at least 2 log10 units after 12 weeks was found to be the optimal definition of an EVR. Among 965 patients, 778 (80%) achieved an EVR by week 12, including all except 1 patient with genotypes 2 or 3. Among 187 patients without an EVR, only 3 (1.6%) had an SVR. These findings suggest that patients with genotype 1 who do not achieve an EVR should stop treatment after 12 weeks. Use of an early stopping rule reduces treatment costs by at least 16% and avoids the inconvenience and side effects of treatment in the 19% of patients without an EVR who have little chance of a lasting virological response.

Ancillary